869884-78-6

Basic information

• Product Name: Radezolid
• Synonyms: radezolid;N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide;Unii-53pc6lo35w;RX 1741;RX-1741;N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-yLmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-ox;(5S)-N-[3-(2-fluoro-4'-{[(1H-[1,2,3]triazol-4-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]acetamide
• CAS NO: 869884-78-6
• Molecular Formula: C₂₂H₂₃FN₆O₃
• Molecular Weight: 438.45
• Mol File: 869884-78-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 712.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.336
• Solubility: ≥43.8 mg/mL in DMSO; insoluble in H2O; ≥18.08 mg/mL in EtOH with gentle warming
• PKA: 15.53±0.46(Predicted)
• CAS DataBase Reference: Radezolid(CAS DataBase Reference)
• NIST Chemistry Reference: Radezolid(869884-78-6)
• EPA Substance Registry System: Radezolid(869884-78-6)

Safety Data

• Hazardous Substances Data: 869884-78-6(Hazardous Substances Data)

Usage

General Description

Radezolid is a novel oxazolidinone antibiotic that is currently in development for the treatment of bacterial infections. It belongs to the same class of antibiotics as linezolid, with similar activity against Gram-positive bacteria, including drug-resistant strains such as MRSA and vancomycin-resistant enterococci. Radezolid works by inhibiting bacterial protein synthesis, and it has shown promising results in early clinical trials in terms of both efficacy and safety. Additionally, its unique chemical structure and mechanism of action may provide it with an advantage over existing oxazolidinone antibiotics. Overall, Radezolid has the potential to be an important new option for treating challenging bacterial infections in the future.

Upstream product

• 627543-03-7 (5S)-5-aminomethyl-3-(3-fluoro-4-iodophenyl)-oxazolidin-2-one 
• 501939-82-8 (5R)-methanesulfonic acid 3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 149524-42-5 (5R)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one 
• 149524-47-0 N-(carbobenzyloxy)-3-fluoroaniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 70978-37-9 1-(azidomethyl)-4-methoxybenzene 
• 87199-17-5 4-formylphenylboronic acid, 
• 2450-71-7 Propargylamine 
• 149524-45-8 (S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 372-19-0 meta-fluoroaniline 
• 916888-21-6 (5S)-N-{3-[2-fluoro-4'-({[1-(4-methoxybenzyl)-1H-[1,2,3]triazol-4-ylmethyl]amino}methyl)biphenyl-4-yl]-2-oxo-oxazolidin-5-ylmethyl}acetamide hydrochloride 

Downstream Products

• 869884-77-5 (5S)-N-[3-(2-fluoro-4'-{[(1H-[1,2,3]triazol-4-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]acetamide hydrochloride 

Relevant articles and documents

METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION

The present invention relates to methods for treating acne and other skin infections caused or mediated by Propionibacterium acnes, Gardnerella vaginalis, or Staphylococcus aureus in a patient with a safe and effective amount of a topically applied oxazolidinone antibiotic compound.

Design at the atomic level: Design of biaryloxazolidinones as potent orally active antibiotics

We have developed a first generation of hybrid sparsomycin-linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant Gram-positive bacteria as well as the fastidi